BioTek reMEDys Revenue and Competitors
Estimated Revenue & Valuation
- BioTek reMEDys's estimated annual revenue is currently $24.7M per year.
- BioTek reMEDys's estimated revenue per employee is $201,000
Employee Data
- BioTek reMEDys has 123 Employees.
- BioTek reMEDys grew their employee count by 13% last year.
BioTek reMEDys's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP, Strategic Healthcare Partnerships | Reveal Email/Phone |
3 | Director Operations | Reveal Email/Phone |
4 | Senior Director Compliance, Contracts & Legal Operations | Reveal Email/Phone |
5 | Director Pharmacy at Biotek Remedys South | Reveal Email/Phone |
6 | Director Enterprise Strategy | Reveal Email/Phone |
7 | Director Quality Management and Clinical Operations | Reveal Email/Phone |
8 | Director Pharmacy at BioTek reMEDys West | Reveal Email/Phone |
9 | IT Department Manager | Reveal Email/Phone |
10 | Pharmacy Manager | Reveal Email/Phone |
BioTek reMEDys Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $34M | 183 | 31% | N/A | N/A |
#2 | $8.4M | 42 | -28% | N/A | N/A |
#3 | $68.7M | 342 | 6% | N/A | N/A |
#4 | $49.4M | 246 | -10% | N/A | N/A |
#5 | $7.8M | 39 | 44% | N/A | N/A |
#6 | $148.3M | 560 | -8% | N/A | N/A |
#7 | $24.7M | 123 | 13% | N/A | N/A |
#8 | $0.8M | 7 | 0% | N/A | N/A |
#9 | N/A | 12 | 50% | N/A | N/A |
#10 | $9M | 40 | 8% | N/A | N/A |
What Is BioTek reMEDys?
We are a national Specialty Pharmacy company providing medications and support services to patients, prescribers, payers and manufacturers.
keywords:N/AN/A
Total Funding
123
Number of Employees
$24.7M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $26.7M | 127 | -1% | N/A |
#2 | $61.6M | 133 | 6% | N/A |
#3 | $60.3M | 136 | -11% | N/A |
#4 | $45.2M | 137 | -1% | N/A |
#5 | $15.7M | 148 | 36% | N/A |